Zacks Investment Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Other analysts also recently issued reports about the company. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Cantor Fitzgerald restated an overweight rating and issued a $130.00 price target (up previously from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Svb Leerink lowered shares of Aclaris Therapeutics from an outperform rating to a market perform rating in a research report on Thursday, June 27th. Leerink Swann lowered shares of Aclaris Therapeutics from an outperform rating to a market perform rating in a research report on Thursday, June 27th. Finally, BidaskClub lowered shares of Zebra Technologies from a buy rating to a hold rating in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Aclaris Therapeutics presently has a consensus rating of Hold and an average target price of $19.69.

Shares of NASDAQ:ACRS traded down $0.13 during midday trading on Monday, hitting $2.20. The company had a trading volume of 371,200 shares, compared to its average volume of 616,464. The firm’s 50-day moving average is $4.03. The company has a current ratio of 4.33, a quick ratio of 4.30 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $92.86 million, a PE ratio of -0.55 and a beta of 0.78. Aclaris Therapeutics has a twelve month low of $1.93 and a twelve month high of $21.02.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). The firm had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. As a group, equities research analysts expect that Aclaris Therapeutics will post -2.87 earnings per share for the current fiscal year.

In other news, major shareholder James E. Flynn sold 339,537 shares of Aclaris Therapeutics stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $4.62, for a total transaction of $1,568,660.94. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn sold 614,710 shares of Aclaris Therapeutics stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $6.13, for a total transaction of $3,768,172.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,107,983 shares of company stock worth $9,303,479. 14.80% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in Aclaris Therapeutics by 43.8% in the fourth quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock valued at $26,759,000 after purchasing an additional 1,103,423 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Aclaris Therapeutics by 71.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,278,364 shares of the biotechnology company’s stock worth $16,837,000 after acquiring an additional 950,781 shares in the last quarter. Sofinnova Investments Inc. increased its position in shares of Aclaris Therapeutics by 24.2% during the fourth quarter. Sofinnova Investments Inc. now owns 1,911,573 shares of the biotechnology company’s stock worth $14,127,000 after acquiring an additional 372,093 shares in the last quarter. Broadfin Capital LLC bought a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $13,875,000. Finally, MFN Partners Management LP bought a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $11,085,000. Institutional investors and hedge funds own 91.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Further Reading: Buy Rating

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.